Amedeo Smart

Free Medical Literature Service




  Free Subscription

Articles published in
Eur Respir J
    January 2024
  1. BURGEL PR, Sermet-Gaudelus I, Girodon E, Kanaan R, et al
    Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare CFTR variants: a viewpoint.
    Eur Respir J. 2024;63:2301959.
    >> Share

    December 2023
  2. SUNDE RB MD PHD, Thorsen J MD PhD, Kim M MSc PhD, Schoos AM MD PhD, et al
    Bacterial Colonization of the Airway in Neonates and Risk of Asthma and Allergy Until Age 18 Years.
    Eur Respir J. 2023 Dec 14:2300471. doi: 10.1183/13993003.00471-2023.
    >> Share

  3. BARRY PJ, Burgel PR
    Cast no shadow: assessing the disease-modifying effects of elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2023;62:2302026.
    >> Share

  4. DAINES CL, Tullis E, Costa S, Linnemann RW, et al
    Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
    Eur Respir J. 2023;62:2202029.
    >> Share

  5. SUCRE JMS, Frank DB
    Having new eyes: MRI for visualisation of pulmonary vascular disease and prediction of bronchopulmonary dysplasia severity.
    Eur Respir J. 2023;62:2302041.
    >> Share

    November 2023
  6. HYSINGER EB, Critser P
    How is preterm birth working out: cardiopulmonary response to exercise in extreme prematurity.
    Eur Respir J. 2023;62:2301787.
    >> Share

    October 2023
  7. WANG KCW, Elliot JG, Saglani S, Donovan GM, et al
    The airway smooth muscle layer is structurally abnormal in low birth weight infants - implications for obstructive disease.
    Eur Respir J. 2023 Oct 12:2301176. doi: 10.1183/13993003.01176-2023.
    >> Share

  8. BEEN JV, Simons SHP, Labrecque JA
    Dexamethasone for preterm infants at risk of bronchopulmonary dysplasia: is timing everything?
    Eur Respir J. 2023;62:2301473.
    >> Share

  9. BEAR C, Ratjen F
    Charting the path to expanded access for CFTR modulator drugs: the nose knows.
    Eur Respir J. 2023;62:2301387.
    >> Share

  10. DREANO E, Burgel PR, Hatton A, Bouazza N, et al
    Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription.
    Eur Respir J. 2023;62:2300110.
    >> Share

  11. HEBESTREIT H, Thornton CS
    Cystic fibrosis and the cardiovascular system: the unexpected heartache.
    Eur Respir J. 2023;62:2301253.
    >> Share

  12. FROST F, Nazareth D, Fauchier L, Wat D, et al
    Prevalence, risk factors and outcomes of cardiac disease in cystic fibrosis: a multinational retrospective cohort study.
    Eur Respir J. 2023;62:2300174.
    >> Share

    September 2023
  13. DELFRATE J, Girard-Bock C, Curnier D, Perie D, et al
    Cardiopulmonary response to exercise in adults born very preterm.
    Eur Respir J. 2023 Sep 21:2300503. doi: 10.1183/13993003.00503-2023.
    >> Share

  14. HAFNER F, Kindt A, Strobl K, Forster K, et al
    MRI pulmonary artery flow detects lung vascular pathology in preterms with lung disease.
    Eur Respir J. 2023 Sep 7:2202445. doi: 10.1183/13993003.02445-2022.
    >> Share

  15. MORRISON L, Thornton CS
    Quality over quantity: the next ACT in airway clearance in cystic fibrosis.
    Eur Respir J. 2023;62:2301354.
    >> Share

  16. FILIPOW N, Stanojevic S, Raywood E, Shannon H, et al
    Real-world effectiveness of airway clearance techniques in children with cystic fibrosis.
    Eur Respir J. 2023;62:2300522.
    >> Share

    August 2023
  17. KWOK TC, Szatkowski L, Sharkey D
    Impact of postnatal dexamethasone timing on preterm mortality and bronchopulmonary dysplasia: a propensity score analysis.
    Eur Respir J. 2023 Aug 17:2300825. doi: 10.1183/13993003.00825-2023.
    >> Share

  18. POWELL WT, Reeves SR
    From small to big, using microRNA profiling to investigate infant origins of childhood asthma.
    Eur Respir J. 2023;62:2301052.
    >> Share

  19. TUNNEY MM, Wark P
    Long-term therapy with elexacaftor/tezacaftor/ivacaftor (ETI) in cystic fibrosis: improved clinical outcomes but infection and inflammation persist.
    Eur Respir J. 2023;62:2301008.
    >> Share

  20. SCHAUPP L, Addante A, Voller M, Fentker K, et al
    Longitudinal effects of elexacaftor/tezacaftor/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis.
    Eur Respir J. 2023;62:2202153.
    >> Share

    July 2023
    More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice.
    Eur Respir J. 2023;62:2300865.
    >> Share

  22. BAYFIELD KJ, Weinheimer O, Boyton C, Fitzpatrick R, et al
    Implementation and evaluation of ultra-low dose CT in early cystic fibrosis lung disease.
    Eur Respir J. 2023;62:2300286.
    >> Share

  23. DWYER TJ, Elkins MR, Dentice R, Forbes S, et al
    Saline at lower tonicity in cystic fibrosis (SALTI-CF) trial comparing 0.9% versus 3% versus 6% nebulised saline.
    Eur Respir J. 2023;62:2100960.
    >> Share

    June 2023
  24. ZHU Z, Freishtat RJ, Harmon B, Hahn A, et al
    Nasal airway microRNA profiling of infants with severe bronchiolitis and risk of childhood asthma: A multicenter prospective study.
    Eur Respir J. 2023 Jun 15:2300502. doi: 10.1183/13993003.00502-2023.
    >> Share

  25. DUIJTS L
    Prematurity-related chronic respiratory disease across the life course.
    Eur Respir J. 2023;61:2300662.
    >> Share

    May 2023
  26. BEHR J
    The art of clinical trial design in pulmonary fibrosis.
    Eur Respir J. 2023;61:2300346.
    >> Share

  27. May Podcast: Cystic fibrosis.
    Eur Respir J. 2023;61:23E6105.
    >> Share

  28. ADDANTE A, Raymond W, Gitlin I, Charbit A, et al
    A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.
    Eur Respir J. 2023;61:2202022.
    >> Share

    April 2023
    The effects of elexafactor/tezafactor/ivacaftor beyond the epithelium: spurring macrophages to fight infections.
    Eur Respir J. 2023;61:2300216.
    >> Share

  30. CAVINATO L, Luly FR, Pastore V, Chiappetta D, et al
    Elexacaftor/tezacaftor/ivacaftor corrects monocyte microbicidal deficiency in cystic fibrosis.
    Eur Respir J. 2023;61:2200725.
    >> Share

  31. ZHANG S, Shrestha CL, Robledo-Avila F, Jaganathan D, et al
    Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor.
    Eur Respir J. 2023;61:2102861.
    >> Share

  32. VAN TONDER AJ, Ellis HC, Churchward CP, Kumar K, et al
    M ycobacterium avium complex genomics and transmission in a London hospital.
    Eur Respir J. 2023;61:2201237.
    >> Share

    March 2023
  33. PULAKKA A, Risnes K, Metsala J, Alenius S, et al
    Preterm birth and asthma and COPD in adulthood: a nationwide register study from two Nordic countries.
    Eur Respir J. 2023 Mar 29:2201763. doi: 10.1183/13993003.01763-2022.
    >> Share

    Children and TB pharmacokinetics: no longer in infancy?
    Eur Respir J. 2023;61:2202003.
    >> Share

  35. ASMUS E, Karle W, Brack MC, Wittig C, et al
    Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients.
    Eur Respir J. 2023;61:2202009.
    >> Share

    February 2023
  36. PEDERSEN ESL, Kuehni CE
    Preventing bronchiolitis among infants with non-pharmaceutical interventions outside pandemics: is it realistic?
    Eur Respir J. 2023;61:2202214.
    >> Share

    January 2023
  37. DHOTE T, Martin C, Regard L, Pesenti L, et al
    Normalisation of circulating neutrophil counts after 12 months of elexacaftor-tezacaftor-ivacaftor in patients with advanced cystic fibrosis.
    Eur Respir J. 2023;61:2202096.
    >> Share

    December 2022
  38. RINGSHAUSEN FC, Sauer-Heilborn A, Buttner T, Dittrich AM, et al
    Lung transplantation for end-stage cystic fibrosis before and after the accessibility of elexacaftor/tezacaftor/ivacaftor, Germany, 2012-2021.
    Eur Respir J. 2022 Dec 14:2201402. doi: 10.1183/13993003.01402-2022.
    >> Share

  39. MITROPOULOU G, Brandenberg N, Hoehnel S, Ceroni C, et al
    Rectal organoid-guided CFTR modulator therapy restores lung function in a cystic fibrosis patient with the rare 1677delTA/R334W genotype.
    Eur Respir J. 2022;60:2201341.
    >> Share

    November 2022
  40. WILLERS CC, Frauchiger BS, Stranzinger E, Bauman G, et al
    Feasibility of unsedated lung MRI in young children with cystic fibrosis.
    Eur Respir J. 2022;60.
    >> Share

    September 2022
  41. BONADIES L, Papi A, Baraldi E
    Is bronchopulmonary dysplasia in adult age a novel COPD endotype?
    Eur Respir J. 2022;60.
    >> Share

  42. UM-BERGSTROM P, Pourbazargan M, Brundin B, Strom M, et al
    Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia.
    Eur Respir J. 2022;60.
    >> Share

    August 2022
    A step forward for an intermediate cystic fibrosis population.
    Eur Respir J. 2022;60.
    >> Share

  44. NGUYEN-KHOA T, Hatton A, Drummond D, Aoust L, et al
    Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test.
    Eur Respir J. 2022;60.
    >> Share

  45. SAFERALI A, Qiao D, Kim W, Raraigh K, et al
    C FTR variants are associated with chronic bronchitis in smokers.
    Eur Respir J. 2022;60.
    >> Share

  46. MUILWIJK D, de Poel E, van Mourik P, Suen SWF, et al
    Forskolin-induced organoid swelling is associated with long-term cystic fibrosis disease progression.
    Eur Respir J. 2022;60.
    >> Share

    July 2022
  47. MURPHY VE, Jensen ME, Holliday EG, Giles WB, et al
    Effect of asthma management with exhaled nitric oxide versus usual care on perinatal outcomes.
    Eur Respir J. 2022 Jul 1. pii: 13993003.00298-2022.
    >> Share

  48. CHASSAGNON G, Campredon A, Vakalopoulou M, Burgel PR, et al
    Diversity of approaches in artificial intelligence: an opportunity for discoveries in thoracic imaging.
    Eur Respir J. 2022;60.
    >> Share

  49. ZHANG B, Zhang S
    Radiomics-derived morphological features predict pulmonary function response during lumacaftor/ivacaftor therapy in patients with cystic fibrosis.
    Eur Respir J. 2022;60.
    >> Share

    May 2022
  50. RIGAUTS C, Aizawa J, Taylor SL, Rogers GB, et al
    R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease.
    Eur Respir J. 2022;59.
    >> Share

    March 2022
  51. ZANNIN E, Rigotti C, Neumann RP, Dellaca RL, et al
    Oscillatory mechanics at 36 weeks post-menstrual age as markers of lung disease in preterm infants: a cohort study.
    Eur Respir J. 2022 Mar 2. pii: 13993003.03023-2021.
    >> Share

  52. KURZ JM, Ramsey KA, Rodriguez R, Spycher B, et al
    Association of lung clearance index with survival in individuals with cystic fibrosis.
    Eur Respir J. 2022;59.
    >> Share

    February 2022
  53. YEH HI, Hwang TC
    In vitro assessment of triple combination therapy for the most common disease-associated mutation in cystic fibrosis.
    Eur Respir J. 2022;59.
    >> Share

  54. HIRANI D, Alvira CM, Danopoulos S, Milla C, et al
    Macrophage-derived IL-6 trans-signalling as a novel target in the pathogenesis of bronchopulmonary dysplasia.
    Eur Respir J. 2022;59.
    >> Share

  55. GOSS CH, Fajac I, Jain R, Seibold W, et al
    Efficacy and safety of inhaled ENaC inhibitor BI 1265162 in patients with cystic fibrosis: BALANCE-CF 1, a randomised, phase II study.
    Eur Respir J. 2022;59.
    >> Share

  56. MORRISON CB, Shaffer KM, Araba KC, Markovetz MR, et al
    Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties via hydration.
    Eur Respir J. 2022;59.
    >> Share

    December 2021
  57. RAITA Y, Perez-Losada M, Freishtat RJ, Hahn A, et al
    Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study.
    Eur Respir J. 2021 Dec 16. pii: 13993003.02293-2021.
    >> Share

  58. GURDENIZ G, Ernst M, Rago D, Kim M, et al
    Neonatal metabolome of cesarean section and risk of childhood asthma.
    Eur Respir J. 2021 Dec 9. pii: 13993003.02406-2021.
    >> Share

  59. KRUIZINGA MD, Essers E, Stuurman FE, Yavuz Y, et al
    Clinical validation of digital biomarkers for pediatric patients with asthma and cystic fibrosis - Potential for clinical trials and clinical care.
    Eur Respir J. 2021 Dec 9. pii: 13993003.00208-2021.
    >> Share

    Primary nasal epithelial cells from patients with cystic fibrosis hold promise for guiding precision medicine and expanding treatment.
    Eur Respir J. 2021;58.
    >> Share

  61. SETTE G, Lo Cicero S, Blacona G, Pierandrei S, et al
    Theratyping cystic fibrosis in vitro in ALI culture and organoid models generated from patient-derived nasal epithelial conditionally reprogrammed stem cells.
    Eur Respir J. 2021;58.
    >> Share

    November 2021
  62. BINGLE CD, Bingle L
    SPLUNC1 comes of age? Predicting acute exacerbations in cystic fibrosis.
    Eur Respir J. 2021;58.
    >> Share

  63. KHANAL S, Webster M, Niu N, Zielonka J, et al
    SPLUNC1: a novel marker of cystic fibrosis exacerbations.
    Eur Respir J. 2021;58.
    >> Share

    October 2021
  64. SATRELL E, Clemm H, Roksund O, Hufthammer KO, et al
    Development of lung diffusion to adulthood following extremely preterm birth.
    Eur Respir J. 2021 Oct 8. pii: 13993003.04103-2020.
    >> Share

    September 2021
  65. HART K, Cousins M, Watkins WJ, Kotecha SJ, et al
    Association of Early Life Factors with Prematurity-Associated Lung Disease: Prospective Cohort Study.
    Eur Respir J. 2021 Sep 29. pii: 13993003.01766-2021.
    >> Share

  66. MARTIN C, Burgel PR
    Improved survival albeit with persistent disparities in prognosis for people with cystic fibrosis in European countries.
    Eur Respir J. 2021;58.
    >> Share

  67. MCKONE EF, Ariti C, Jackson A, Zolin A, et al
    Survival estimates in European cystic fibrosis patients and the impact of socioeconomic factors: a retrospective registry cohort study.
    Eur Respir J. 2021;58.
    >> Share

    July 2021
  68. WECKMANN M, Bahmer T, Bulow Sand JM, Rank Ronnow S, et al
    COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy.
    Eur Respir J. 2021 Jul 29. pii: 13993003.03969-2020.
    >> Share

    June 2021
  69. CORIATI A, Sykes J, Lemonnier L, Ma X, et al
    The impact of the high emergency lung transplantation program in cystic fibrosis in France: insight from a comparison with Canada.
    Eur Respir J. 2021 Jun 17. pii: 13993003.00014-2021.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016